Inborn errors of metabolism and expanded newborn screening: review and update
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Inborn errors of metabolism (IEM) are a phenotypically and genetically heterogeneous group of disorders caused by a defect in a metabolic pathway, leading to malfunctioning metabolism and/or the accumulation of toxic intermediate metabolites. To date, more than 1000 different IEM have been identified. While individually rare, the cumulative incidence has been shown to be upwards of 1 in 800. Clinical presentations are protean, complicating diagnostic pathways. IEM are present in all ethnic groups and across every age. Some IEM are amenable to treatment, with promising outcomes. However, high clinical suspicion alone is not sufficient to reduce morbidities and mortalities. In the last decade, due to the advent of tandem mass spectrometry, expanded newborn screening (NBS) has become a mandatory public health strategy in most developed and developing countries. The technology allows inexpensive simultaneous detection of more than 30 different metabolic disorders in one single blood spot specimen at a cost of about USD 10 per baby, with commendable analytical accuracy and precision. The sensitivity and specificity of this method can be up to 99% and 99.995%, respectively, for most amino acid disorders, organic acidemias, and fatty acid oxidation defects. Cost-effectiveness studies have confirmed that the savings achieved through the use of expanded NBS programs are significantly greater than the costs of implementation. The adverse effects of false positive results are negligible in view of the economic health benefits generated by expanded NBS and these could be minimized through increased education, better communication, and improved technologies. Local screening agencies should be given the autonomy to develop their screening programs in order to keep pace with international advancements. The development of biochemical genetics is closely linked with expanded NBS. With ongoing advancements in nanotechnology and molecular genomics, the field of biochemical genetics is still expanding rapidly. The potential of tandem mass spectrometry is extending to cover more disorders. Indeed, the use of genetic markers in T-cell receptor excision circles for severe combined immunodeficiency is one promising example. NBS represents the highest volume of genetic testing. It is more than a test and it warrants systematic healthcare service delivery across the pre-analytical, analytical, and post-analytical phases. There should be a comprehensive reporting system entailing genetic counselling as well as short-term and long-term follow-up. It is essential to integrate existing clinical IEM services with the expanded NBS program to enable close communication between the laboratory, clinicians, and allied health parties. In this review, we will discuss the history of IEM, its clinical presentations in children and adult patients, and its incidence among different ethnicities; the history and recent expansion of NBS, its cost-effectiveness, associated pros and cons, and the ethical issues that can arise; the analytical aspects of tandem mass spectrometry and post-analytical perspectives regarding result interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chace, D. H., Kalas, T. A., & Naylor, E. W. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.022502.103213 · Cited by 210
Newborn screening strategies for congenital hypothyroidism: an update
LaFranchi, S. H. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9062-1 · Cited by 121
HUBBARD, W., MOSER, A., TORTORELLI, S., LIU, A., JONES, D., & MOSER, H. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.05.001 · Cited by 108
Current status of neonatal screening for congenital adrenal hyperplasia
Pang, S., & Shook, M. K. (1997) · Current Opinion in Pediatrics · doi:10.1097/00008480-199708000-00018 · Cited by 104
Schwarz, E., Liu, A., Randall, H., Haslip, C., Keune, F., Murray, M., Longo, N., & Pasquali, M. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181aa3777 · Cited by 97
Abdallah, M. W., Larsen, N., Mortensen, E. L., Atladóttir, H. Ó., Nørgaard-Pedersen, B., Bonefeld-Jørgensen, E. C., Grove, J., & Hougaard, D. M. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.07.013 · Cited by 94
Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia
Sarafoglou, K., Banks, K., Gaviglio, A., Hietala, A., McCann, M., & Thomas, W. (2012) · PEDIATRICS · doi:10.1542/peds.2012-1219 · Cited by 69
Public Attitudes Regarding the Use of Residual Newborn Screening Specimens for Research
Botkin, J. R., Rothwell, E., Anderson, R., Stark, L., Goldenberg, A., Lewis, M., Burbank, M., & Wong, B. (2012) · Pediatrics · doi:10.1542/peds.2011-0970 · Cited by 68
Sander, J., Janzen, N., Peter, M., Sander, S., Steuerwald, U., Holtkamp, U., Schwahn, B., Mayatepek, E., Trefz, F. K., & Das, A. M. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059790 · Cited by 62
Kösel, S., Burggraf, S., Fingerhut, R., Dörr, H. G., Roscher, A. A., & Olgemöller, B. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.042416 · Cited by 52
Cited by
Half a century of amyloids: past, present and future
Ke, P. C., Zhou, R., Serpell, L. C., Riek, R., Knowles, T. P. J., Lashuel, H. A., Gazit, E., Hamley, I. W., Davis, T. P., Fändrich, M., et al. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00199a · Cited by 568
Fawaz, R., Baumann, U., Ekong, U., Fischler, B., Hadzic, N., Mack, C. L., McLin, V. A., Molleston, J. P., Neimark, E., Ng, V. L., et al. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001334 · Cited by 555
Metadata
- Authors
- Mak, C. M., Lee, H.-C. H., Chan, A. Y.-W., & Lam, C.-W.
- Venue
- Critical Reviews in Clinical Laboratory Sciences
- Publisher
- Informa UK Limited
- Published
- 2013-11
- Volume
- 50
- Issue
- 6
- Pages
- 142-162
- ISSN
- 1040-8363 (ISSN-L)
- 1549-781X
- OpenAlex
- W2085816680
- Cited by
- 201
- References
- 11
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inborn errors of metabolism and expanded newborn screening: review and update. https://app.cochat.ai/papers/10.3109/10408363.2013.847896
- The paper
- Mak, C. M., Lee, H.-C. H., Chan, A. Y.-W., & Lam, C.-W. (2013). Inborn errors of metabolism and expanded newborn screening: review and update. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.3109/10408363.2013.847896
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.